for and Thank thank today. joining you Ping. Good us evening, you
future. of store I begin, are the Dyadic in how of potential of scientific be the XXXX. in excited full with the ahead for for world, Before and we the is proud to accomplishments are seeing early the to and optimism synthetic we still just But Dyadic of biology business just in we’re year to this share what team’s we days hold wanted in part
forward the of biology and patented and one and is In are To platforms our for year’s look call CX goals calendar for synthetic accounted the become our food primary on we following protein The our platform investor for proud applications, which development medical segments we year. focus goals you, applications leading technologies categorized agriculture, other of to synthetic biology applications. to the commercial and segments, synthetic As biology applications, remains but production the production. of share into this CX’s medical end, environmental XXXX, not the to the XXXX market platform. industrial proprietary leveraging also update this manufacturing first protein largest our with only share market, new into progress
us As year as that fuel to company’s milestones mission staying operating improve you for the new This made world. sets while feed have know, we mission. we heal a the it and to to clear true way hit that
to and call global the our to of commercialization supports today’s strategy, Officer, has Hazelton focus role Chief licensing. appointment business initiatives, is new, whose away Joe and renewed corporate existing the to as hope I and including with team While the Business the business from of our enhanced leadership take level. development company, you next mission ability and expanded take Dyadic We the it corporate
related partnering and coupled ourselves tackle better company’s have and in with and the of influx knowledge experience technologies. CX interests the to to platform advancement of requests a the We put position our global other
industries protein testing of of penetrate commercial our human potential some our industrial papers and and in industries and production entering the we food development concept of using today, new endeavors. these published manufacturing, animal are proof that by it largest a we other enterprises internal to our of platform of are we are industries CX be years the we or preclinical technologies health, believe advanced several after development Additionally, period and targeting across the growth research highlighted
As we fully with funding are organizations non-COVID-XX COVID-XX vaccine programs as technologies included Health, and human us commercialization core around helping focus of and that production our candidate. been instrumental efforts commercial Phibro biomolecules, health, of our and the of on the and multitude biopharmaceutical as accomplishments, other these our CX animal advancing protein a the proprietary advance Janssen Animal partnerships well world have health, platform DYAI-XXX development number have to of our verticals and examples of major other viability
to We safety scientific produced and that against efficacy in and cells from journals, manuscripts vaccines. three are reviewed showing to SARS-CoV-X models animal antigens were CX pleased pair and published note influenza relating including
publication RBD completed study A reviewed We has in Pathology. These preclinical exciting a other journal candidate. other scientific of us vaccine safety COVID-XX studies human manuscript for efficacy in persistence demonstrate among have the our the from DYAI-XXX of successfully produced properties awaiting health. been are and peer the antigen toxicology a of SARS-CoV-X and Toxicologic as benefits safety, number structures biochemical that showing
and influenza expediting In addition, utility pandemic of protein seasonal publications cell production antigen, CX demonstrated to vaccines. in also of intranasally platform and method the and deliver separately, CX novel SARS-CoV-X the these a subcutaneously RBD the
efforts these in areas revolutionize application metabolic middle focused the in proteins. food years have other regarding ubiquitous active industrial manufacturing, have address refocused pivot our steady we agriculture, CX antibodies into to begun firmly engineering. We remain already plus CX We outbound research biopharmaceutical our leverage health to XX production the income on of knowledge which of funded continue We’ve awareness of uses protein conduct production, and inequity the believe advancement begun biomanufacturing. to our of and you and medicinal to manufacturing improved countries. proven across of platform potential to and as therapeutic of lower that We vaccines, have
or vaccines, which storage to distribute and cold vaccine on advanced and outside require sources which production reliant resources the techniques. We’re and store drug infrastructure of lack
in we continue CX the candidate to our into across COVID-XX is other an we vaccines While And happening we in relationships arena emphasize deliver platform Africa, but vaccine we to move clinic, applications, interest want years, only the addition DYAI-XXX will numerous collaboration, Americas. for the therapeutics. in through not our believe continue Asia, U.S., Europe, this and India, in to in that to and
ahead structured forms Biotech by earn therapeutic continues we efforts outs. cell press upfront Dyadic’s candidates our some to maintain already production these As forward, future these cover we payments, targets. J&J partnerships releases. A platform With as to We quickly include other royalty have move move major the against upfront which biologic the development production call to with said, this of our through commercial several to for innovation. of protein highlights, to protein facilitated milestones, the want announced Janssen’s cell received utilize that of own in payment Dyadic reiterate win of rights $XXX,XXX develop I company lines to our CX we or with recent CX Janssen for IP of and partnerships in non-exclusive recent agreement based announcement Janssen their the let’s manufacturing
believe around payments, expect milestones, would of we’ll As which future forms as our expression, efforts up new revolutionize turn or ability upfront protein CX’s and team’s payments. awareness to to in trigger, we come expand we we royalties, to similar continue ramp agreements business other continues to see commercial development,
that to Rescue vaccine. animal broadening produce to Additionally, lead agreement they good CX derived start. continue concept vaccine single project be We the commercialization a two conditions measures up development the we and speed be term to for funding to our mineral received with This candidates and effective The White to €X.X biologics, engineer CX and Therapeutics between product sheet follows a a disagreement a to to expect parties a which R&D of a for announced of announced American including a license lines this terms working a compared institute provided is pandemics. from sheet on companies. for relationship specific company. cells. to have terminate development million could of of Janssen, March state-of-the-art additional successful entry Earlier concerned trials grant that work, In and timing of recently in develop for grant previously the off that agreement The manufacturing in the Sorrento announced, entered we agreement to advantage previously production parties CX an developing due the of NIIMBL this the parties Dyadic the agreement Phibro NIIMBL nutrition to particular is of targeted to candidates. Health we mutually ability counter future the two cell and We’ve the to XXXX. current House to the exclusive produce into under will license order a coronavirus the health national vaccines were completed to Animal company poultry antigen produced diversified The with benchmark up methods, and manufacturing rapid global animal antibodies. response XX, CX its December, Plan have month, animal to the platform assess leading announced for agreed with and medical by $XXX,XXX proof term intended will
to not Novovet termination license We notice to Bio Luina also a as letter raise XXXX capital Bio, have sent continue the able program. they related to our been with Luina agreement February in
our changed As as partner’s of in ongoing focus our has terminations an part over time, business. these view business needs we
of hard renewed fronts the Phibro as development fruit. are and Janssen both bearing However, great and development of efforts research years work as our on and of multiple well CX, are business how examples
several first move who company’s have trials. the certain concept a development last towards proof maturity cycle indications a followed to in-human life company of as from a to the partnering and those collaboration and we commercialization all feasibility over studies For and technology marked towards years,
Consortium Africa X developing on to proteins vaccine independence further produce Dyadic’s vaccine development potential preparing serve the products a to Products Health CX arrangement vaccine clinical validate Phase Establish entered variant manufacturing for pathway transfer and perspective, progress and transmission drug CRXX, to South Rubic COVID-XX variants develop with are primary but vaccines including a licensing the safe lines research, of to and we developing DYAI-XXX and Consortium CX vaccine DYAI-XXX Rubic, proof X COVID design scientists, Moving solutions vaccine as clinical for COVID-XX trial may but process current development for South in This not It’s us of will other and intention trial infection application, in important trial suppliers. current global license who This note into for others reason for CX X data CX CTA South wanted and approval evolving. and Wits treatments, of multiple to suggests addition COVID-XX Africa experienced Africa, on be rather collaborations. Well, Wits away research in is foreign funding Pfizer’s This for so-called existing site marketplace to generation effective for to today. a with from of technology note of the some the next partnership call trial COVID-XX technology – Africa. Consortium the It’s coordination only which with agreement. severity A many, the familiar also partnering our agreement testing COVID-XX to vaccine controlling access identified, the managing very the gives (Pty) ability candidate infection platform That symptom on how generation is the South from trials. pharma. from and big manufacturing, rates. out why Rubic evolved. partnering the AstraZeneca Parexel COVID-XX front absence global and the first Authority, We carrying perspective, Wits a institutions in The with and Limited discuss Africa now that for an already guideline South a end vaccine, were the of who evolving to many end clinical a phases clinical and manufactured or We concept unprecedented in disease potential Current has process. including as of adoption. in ongoing the as African of candidates. rates reduce In co-development DYAI-XXX a R&D treating important several especially the clinical and landscape COVID-XX transfer that COVID-XX and Phase is with to still time working to SAPHRA. Wits, vaccine the a in and regulatory We’ve humans vaccines transmission to on Africa’s accelerate shift regulatory to a discovery, said, our in out well African also Regulatory the in begun basis highly African to leading COVID-XX, Consortium and South amidst the as been COVID-XX importance the includes variants vaccine submission global the Health of diminishing have the certain for other pandemic, market. trials control has the take carrying remain FDA’s concern. admitted of testing a clinical South against clinical that as
potential being against However, the disease. exceptions, sub particularly Omicron variants severe variant and
receptor cell have Omicron same alpha, South had India, CX and protection current XX line, may from global The some this degree the needed emerging CX production the will same the that insert the The original emergence company immunization only SARS-CoV-X genes However, Wuhan, protein overcome beta, in strategies days. to Omicron addition Africa, the into the highlighting emerge its effectively CX to rapidly the SARS-CoV-X, gamma, cells, variant risk. with can variants approximately far, the in concern. variants delta, platform new produced we can Thus B.X.X.XXX. Brazil, are of induced variant of possible domain vaccines following successfully and support already cell variant been the against UK, binding genotype
of against the One goals protect is to of COVID-XX different commercial which to effective could at once. of combinations capability rapidly demonstrate Dyadic multivalent variants produce vaccines, of several concern
trials, industries. providing pharmaceutical development global organization of company serves and We not with continue manufacturing to company research and X,XXX employees. stage goods integrated drug Syngene the drug clinical major contract a development, manufacturing the early consumer and conducts manufacturing is headcount work with product services, health and Syngene substance and animal and development preclinical only chemical an in biologics India, International manufacturing and but and biotechnology scientific research, nutrition, industry, services. The other special industry, over
In to in the Phase approval COVID-XX India recently the using Dyadic’s CX cell towards sources. centered use contribute In platform, traditional planning receive advancing of other with and approximately protein their production to produce plans funding a Biotech of funding government line production the framework technology XXXX, a cell discussions across Our manufacturing offerings to company for entered therapeutic with is of into from an for Phase production trials manufacturing Syngene usage clinical the option XX% trials. our stage other vaccines, technology commercial government clinical must India platform agreement human those the antibodies CHO-cell early from proteins. vaccine. Epygen X order to conduct forward vaccine for Epygen around non-exclusive CX technologies who in procured and of in-house on as funding, protein Epygen to it and move the X India,
University mice A a of therapeutically be useful an scheduled clinical or of are highlighted synthetic Oslo. During biomolecule others cannabidiol its precursors are included loss speak, order and Other Scientific hemagglutinin commercially lethal adjuvant of engineered are our company ASXX produced CBD as CX II we compounds, with the with expanded combined mice vaccinated Oslo inquiries, proven cannabis a A/HXNX dose with and showed using demonstrate influenza the homologous X/XXXX, the also results that and having signs, cells its antigens California manufacture no with to of and industrially no biology. challenge can trials the in viable with collaboration vaccine XXXX, weight MHC were ongoing influenza and fully CX the influenza, to including part mice protected. we CX with launch SARS-CoV-X have University. development of produced XLBXX inbound
efficient As methods compared apply through example sativa. synthetic to of effectively we we’re use Ping a continue, the our manufacture CX Rawson? for as acceptance, engineer processes potentially CFO improve, this, pure potential synthetic conventional to I’ll develop and uses therapeutic marijuana cannabis our to turn for demonstrating call biology financials, cell This just to starting to cannabinoids more the for how cannabinoids help more over And hemp is bio plant are CX’s to and applications. run with potential cheaper another number to using commercial
